Antineoplaston A3

Antineoplaston A3 is a peptide-based small molecule derivative developed by the Burzynski Clinic for the treatment of various cancers. It belongs to a class of compounds known as antineoplastons, which were originally identified and isolated from human urine and blood by Dr. Stanislaw Burzynski. The drug is administered via intravenous injection and is proposed to act as a "biochemical corrector" or "molecular switch" that normalizes the phenotype of neoplastic cells by modulating gene expression and signal transduction pathways. Despite being the subject of numerous Phase 1 and Phase 2 clinical trials over several decades, Antineoplaston A3 and related compounds remain highly controversial within the oncology community, as their efficacy and safety have not been established in large-scale, randomized Phase 3 trials, and they have not received regulatory approval from the FDA.

Other names

A3A-3A 3